## NLRP3/AIM2-IN-3

MedChemExpress

®

Cat. No.:	HY-144226		
CAS No.:	1787787-60-	-3	
Molecular Formula:	$C_{16}H_{14}N_{2}O_{2}$		
Molecular Weight:	266.29		
Target:	NOD-like Receptor (NLR); AIM2; Pyroptosis		
Pathway:	Immunology/Inflammation; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (938.83 mM; Need ultrasonic) Methanol : 50 mg/mL (187.77 mM; Need ultrasonic)					
		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	3.7553 mL	18.7765 mL	37.5530 mL	
		5 mM	0.7511 mL	3.7553 mL	7.5106 mL	
		10 mM	0.3755 mL	1.8777 mL	3.7553 mL	
	Please refer to the solubility information to select the appropriate solvent.					

Description	NLRP3/AIM2-IN-3 (compound 59) is a potent inhibitor with differential species specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. NLRP3/AIM2-IN-3 shows inhibitory efficacy against pyroptosis in THP-1 macrophages stimulated with LPS/nigericin, with an IC <sub>50</sub> of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 disturbs the interaction of NLRP3 or AIM2 with the adaptor protein ASC and inhibited ASC oligomerization <sup>[1]</sup> .				
IC <sub>50</sub> & Target	NLRP3				
In Vitro	NLRP3/AIM2-IN-3 (0-100 μM) displays remarkable inhibitory activity against NLRP3-and AIM2-but not NLRC4-dependent activation of caspase-1 and the release of IL-1b in human THP-1 macrophages <sup>[1]</sup> . NLRP3/AIM2-IN-3 shows inhibition of IL-1b secretion by human THP-1 macrophages, with IC <sub>50</sub> of 0.098 μM, which is nearly 150-fold and 500-fold more potent than that of J774A.1 (14.62 μM) and bone marrow-derived macrophages (BMDMs) (48.98 μM), respectively <sup>[1]</sup> . NLRP3/AIM2-IN-3 has almost no inhibitory effect on the AIM2 inflammasome-dependent activation of caspase-1 and release of IL-1b in J774A.1 cells <sup>[1]</sup> .				

∏ O

HO

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Jiao Y, et al. Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. Eur J Med Chem. 2022 Feb 11;232:114194.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA